Anti-inflammatory effects of total alkaloids from Rubus aleaefolius Poir. on non-alcoholic fatty liver disease through regulation of the NF-κB pathway Erratum in /ijmm/33/4/1048

Zhao,Jinyan; Zheng,Haiyin; Liu,Yan; Lin,Jiumao; Zhong,Xiaoyong; Xu,Wei; Hong,Zhenfeng; Peng,Jun

doi:10.3892/ijmm.2013.1281

Anti-inflammatory effects of total alkaloids from Rubus aleaefolius Poir. on non-alcoholic fatty liver disease through regulation of the NF-κB pathway

Erratum in: /ijmm/33/4/1048

Authors:
- Jinyan Zhao
- Haiyin Zheng
- Yan Liu
- Jiumao Lin
- Xiaoyong Zhong
- Wei Xu
- Zhenfeng Hong
- Jun Peng
View Affiliations

Affiliations: Fujian Academy of Integrative Medicine, Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, Department of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China
Published online on: February 20, 2013 https://doi.org/10.3892/ijmm.2013.1281
Pages: 931-937

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We aimed to explore the anti-inflammatory effects of total alkaloids in Rubus aleaefolius Poir. (TARAP) on non-alcoholic fatty liver disease, and to investigate the possible molecular mechanisms. A rodent non-alcoholic fatty liver disease (NAFLD) model was established by administration of a modified high-fat diet ad libitum for 8 weeks. Rats were treated with polyene phosphatidylcholine (PP), TARAP low‑dose (0.72 g/kg body weight/day) and TARAP high-dose (1.44 g/kg body weight/day). The model group and the control group received distilled water. After treatment for 4 weeks, the blood samples were obtained from the abdominal aorta, and the levels of serum ALT, AST, GGT, ALP, TG, TC, HDL-C and LDL-C were measured. Changes in liver tissue morphology were evaluated by H&E staining. The expression levels of nuclear factor (NF)-κB, cyclooxygenase-2 (COX‑2), interleukin (IL)-6 and tumor necrosis factor (TNF)-α in rat livers were assayed by reverse transcription‑polymerase chain reaction (RT-PCR) and immunohistochemistry. Both TARAP and PP attenuated hepatic steatosis induced by the high-fat diet. The modified high-fat diet caused a significant increase in ALT, AST, GGT, ALP, TG, TC, LDL-C levels and a decrease in HDL-C levels. TARAP and PP treatment abrogated the increase in the levels of liver enzymes and the levels of TG, TC, LDL-C, as well as suppressed the increase in HDL-C levels. The results of RT-PCR and immunohistochemical assay showed that PP and TARAP treatment decreased the expression of NF-κB, COX-2, IL-6 and TNF-α. In conclusion, these results suggest that TARAP may protect against NAFLD through regulation of the NF-κB pathway.

View Figures

View References

1	de Alwis NM and Day CP: Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 48:S104–S112. 2008.PubMed/NCBI
2	Angulo P, Keach JC, Batts KP and Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 30:1356–1362. 1999. View Article : Google Scholar : PubMed/NCBI
3	Matteoni CA, Younossi ZM, Gramlich T, et al: Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116:1413–1419. 1999. View Article : Google Scholar : PubMed/NCBI
4	Teli MR, James OF, Burt AD, et al: The natural history of non-alcoholic fatty liver: a follow-up study. Hepatology. 22:1714–1719. 1995. View Article : Google Scholar : PubMed/NCBI
5	Day CP and James OFW: Steatohepatitis: a tale of two ‘hits’? Gastroenterology. 114:842–845. 1998.
6	Cortez-Pinto H, de Moura MC and Day CP: Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol. 44:197–208. 2006. View Article : Google Scholar : PubMed/NCBI
7	Chen CH, Huang MH, Yang JC, et al: Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 40:745–752. 2006. View Article : Google Scholar : PubMed/NCBI
8	Bellentani S, Saccoccio G, Masutti F, et al: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 132:112–117. 2000. View Article : Google Scholar : PubMed/NCBI
9	Shen L, Fan JG, Shao Y, et al: Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol. 9:1106–1110. 2003.PubMed/NCBI
10	Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
11	Bugianesi E, McCullough AJ and Marchesini G: Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 42:987–1000. 2005. View Article : Google Scholar : PubMed/NCBI
12	McCullough AJ: Update on non-alcoholic fatty liver disease. J Clin Gastroenterol. 34:255–262. 2002. View Article : Google Scholar : PubMed/NCBI
13	Lawrence T, Gilroy DW, Colville-Nash PR and Willoughby DA: Possible new role for NF-κB in the resolution of inflammation. Nat Med. 7:1291–1297. 2001.
14	Riehemann K, Behnke B and Schulze-Osthoff K: Plant extracts from stinging nettle (Urtica dioica), an antirheumatic remedy, inhibit the proinflammatory transcription factor NF-κB. FEBS Lett. 442:89–94. 1999.PubMed/NCBI
15	Renard P and Raes M: The proinflammatory transcription factor NF-kappaB: a potential target for novel therapeutical strategies. Cell Biol Toxicol. 15:341–344. 1999. View Article : Google Scholar : PubMed/NCBI
16	Makarov SS: NF-κB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today. 6:441–448. 2000.
17	Ywsilada E, Ustun O, Sezik E, et al: Inhibitory effect of Turkish folk remedies on inflammatory cytokines: interleukin-1α, interleukin-1β and tumor necrosis factor α. J Ethnopharmacol. 58:59–73. 1997.PubMed/NCBI
18	Costantino L, Albasini A, Rastelli G and Benvenuti S: Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase. Planta Med. 58:342–344. 1992. View Article : Google Scholar : PubMed/NCBI
19	Wang SY and Lin HS: Antioxidant activity in fruits and leaves of blackberry, raspberry, and strawberry varies with cultivar and development stage. J Agric Food Chem. 48:140–146. 2000. View Article : Google Scholar : PubMed/NCBI
20	Alonso R, Cadavid I and Calleja JM: A preliminary study of hypoglycemic activity of Rubus fruticosus. Planta Med. 7(Suppl): S102–S106. 1980. View Article : Google Scholar
21	Lee JH, Ham YA, Choi SH, et al: Activity of crude extract of Rubus crataegifolius roots as a potent apoptosis inducer and DNA topoisomerase I inhibitor. Arch Pharm Res. 23:338–343. 2000.
22	Rauha JP, Remes S, Heinonen M, et al: Antimicrobial effects of Finnish plant extracts containing flavonoids and other phenolic compounds. Int J Food Microbiol. 56:3–12. 2000. View Article : Google Scholar : PubMed/NCBI
23	Hong ZF, Li TJ and Zhao JY: Effect of total alkaloids of Rubus aleaefolius Poir on gene expressions of CYP2E2 and CYP3A1 in rats with acute liver injury. Zhongguo Zhong Xi Yi Jie He Za Zhi. 29:711–715. 2009.(In Chinese).
24	Lin JM, Zhao JY, Li TJ, et al: Hepatoprotection in a rat model of acute liver damage through inhibition of CY2E1 activity by total alkaloids extracted from Rubus alceifolius Poir. Int J Toxicol. 30:237–243. 2011. View Article : Google Scholar : PubMed/NCBI
25	Brunt EM: Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol. 22:330–338. 2005. View Article : Google Scholar : PubMed/NCBI
26	Bellentani S and Tiribelli C: The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol. 35:531–537. 2001. View Article : Google Scholar : PubMed/NCBI
27	Brunt EM: Pathology of nonalcoholic steatohepatitis. Hepatol Res. 33:68–71. 2005. View Article : Google Scholar : PubMed/NCBI
28	Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43(Suppl 1): S99–S112. 2006. View Article : Google Scholar : PubMed/NCBI
29	Ye HZ, Hong ZF, Wang YH and Chen YH: Effects of crude extract of Rubus Alcaefolius Poir on experimental liver injury in rats. Chin Arch Tradit Chin Med. 23:829–831. 2005.
30	Yamaguchi K, Yang L, McCall S, et al: Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 45:1366–1374. 2007. View Article : Google Scholar
31	Bonizzi G and Karin M: The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25:280–288. 2004. View Article : Google Scholar : PubMed/NCBI
32	Baldwin AS Jr: The NF-kappaB and I-kappaB proteins: new discoveries and insights. Annu Rev Immunol. 14:649–683. 1996. View Article : Google Scholar : PubMed/NCBI